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OBJECTIVES: A budget impact model (BIM) was developed to
estimate the economic impact of introducing beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
persistent asthma in most important Autonomous Communities
in Spain. METHODS: Analytic model was based on data from
disease prevalence, population growth, drug consumption, retail
prices and market shares forecasting for most representative
Autonomous Communities in Spain: Andalusia, Catalonia,
Madrid, Vasc Country and Valencia. It takes the perspective of
the Spanish National Pharmaceutical budget and time horizon
considered was 5 years (5% annual discount rate). Drugs con-
sidered in the study were ﬂuticasone/salmeterol, budesonide/
formoterol and beclomethasone/formoterol extraﬁne. The model
estimates the annual cost to treat patients with moderate to
severe persistent asthma before and after the introduction of
beclomethasone/formoterol extraﬁne. Costs are referred to year
2008. RESULTS: According to demographic forecasts and
asthma prevalence, target population with moderate to severe
persistent asthma treated with ﬁxed dose combinations would
be around 104,634 patients in year 2007 in Andalusia, 54,362
in Catalonia, 36,727 in Madrid, 16,311 the Vasc Country and
35,132 in Valencia. On average, cost per patient was estimated at
€982 before the introduction of beclomethasone/formoterol
extraﬁne on the Spanish pharmaceutical market and at €964
after its introduction. CONCLUSIONS: This study estimates
that the introduction of beclomethasone/formoterol extraﬁne for
the treatment of moderate to severe persistent asthma on differ-
ent Autonomous Communities is going to represent a net savings
in the pharmaceutical budget during the next 5 years of around
€11 million in Andalusia, €5.8 million in Catalonia, €4 million in
Madrid, €1.7 in the Vasc Country and €3.9 in Valencia.
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OBJECTIVES: Tobacco use is a signiﬁcant cause of morbidity
with consequent marked economic burden. So far, smoking ces-
sation (SC) medications are not reimbursed in Finland. We evalu-
ated the current and future costs of smoking related diseases
for society and the potential returns for investments in SC.
METHODS: We estimated minimum and maximum smoking
attributable proportions of relevant diseases from literature.
Comprehensive population based Finnish registry data was
combined to evaluate major expenditures (health care costs,
sick-leave compensations, disability pensions, and loss of pro-
ductivity) in 2006 euros from 1996 to 2006. Future expenses
were extrapolated from relevant data and the inﬂuence of SC
assessed in models with several survival patterns. Models were
ﬁtted with three SC medications with different efﬁcacies
(A = 5%, B = 10% and C = 20% success) and one-time costs
(starting from A = €100, B = €200, C = €300 per patient). Return
on investment for government provided drug administration
to 20 000 patients from 2008 to 2017 was calculated for all
options. RESULTS: In the minimum tobacco inﬂuence scenario,
total annual societal costs of smoking attributed morbidities
were €290M with health care costs of €145M (year 2006). This
scenario yielded an increase in real total costs to €376M by 2030.
Respective estimations in maximum scenario were €554M,
€280M and €717M. By subsidizing a free withdrawal drug
delivery for 10 years, the government incurred a cost of €2.3M
(A) €4.5 (B) and €6.8M (C), but received net present value (NPV)
of €29M (A), €57M (B) and €130M (C), through savings from
decreased health related expenditures (5% discount rate used).
Values in the maximum scenarios were €66M, €131M and
€227M. Tobacco tax was not included in the analysis. CON-
CLUSIONS: The costs of smoking for society are projected to
increase during the near future. Our models show that subsidy of
SC drugs is a sound investment.
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OBJECTIVES: To evaluate the cost-effectiveness of the empirical
oral moxiﬂoxacin treatment in Acute Exacerbation of Chronic
Bronchitis (AECB) including clinical failure caused by antimicro-
bial resistance in Germany. METHODS: A decision analytic
model was developed in AECB to estimate clinical success and
failure of oral antimicrobial treatment initiated in the commu-
nity. Three common pathogens, S.pneumoniae, H.inﬂuenzae, and
P.aeruginosa (and other gram-negative) were included using their
relative frequencies. Resistance rates were obtained from litera-
ture. A pooled analysis of seven randomised clinical trials
provided all clinical evidence for moxiﬂoxacin, macrolides and
beta-lactams, using results from the per-protocol population as
representative of non-resistant efﬁcacy and intent-to-treat popu-
lation in sensitivity analyses. Natural host resolution from
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